[A16-53] Necitumumab (lung cancer) - Addendum to Commission A16-17
Last updated 15.09.2016
Project no.: A16-53
Commission: Commission awarded on 08.08.2016 by the Federal Joint Committee (G-BA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Federal Joint Committee (G-BA)
2016-09-15 A G-BA decision was published.